Search research articles
Contact Us
Filters
Showing results (131-140 of 225) with videos related to
Page
of 23
Sort By:
American Journal of Hematology
|
November 15, 2021
Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy
Relja Popovic, Fengjiao Dunbar, Charles Lu, et al.
Blood Advances
|
March 27, 2024
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia
Paul J Hampel, Mahesh Swaminathan, Kerry A Rogers, et al.
Leukemia
|
July 24, 2025
Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies
Stephen J F Chong, Jolin X H Lai, Kartini Iskandar, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 23, 2026
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Jennifer L Crombie, Austin I Kim, Robert Redd, et al.
Blood
|
July 12, 2019
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
Philipp B Staber, Marco Herling, Mar Bellido, et al.
Molecular Cancer
|
March 2, 2025
BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia
Stephen Jun Fei Chong, Junyan Lu, Rebecca Valentin, et al.
Biorxiv : the Preprint Server for Biology
|
November 28, 2023
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine
Alberto J Arribas, Eugenio Gaudio, Sara Napoli, et al.
Blood Advances
|
January 8, 2024
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study
Marco Herling, Claire Dearden, Francesco Zaja, et al.
Blood
|
April 27, 2019
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
Andrew W Roberts, Shuo Ma, Thomas J Kipps, et al.
Haematologica
|
May 27, 2014
Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation
Kazuyuki Murase, Haesook T Kim, O R Gregory Bascug, et al.
Page
of 23
Search research articles
Search
Showing results (131-140 of 225) with videos related to
Sort By:
Page
of 23
American Journal of Hematology
|
November 15, 2021
Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy
Relja Popovic, Fengjiao Dunbar, Charles Lu, et al.
Blood Advances
|
March 27, 2024
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia
Paul J Hampel, Mahesh Swaminathan, Kerry A Rogers, et al.
Leukemia
|
July 24, 2025
Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies
Stephen J F Chong, Jolin X H Lai, Kartini Iskandar, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 23, 2026
A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Jennifer L Crombie, Austin I Kim, Robert Redd, et al.
Blood
|
July 12, 2019
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
Philipp B Staber, Marco Herling, Mar Bellido, et al.
Molecular Cancer
|
March 2, 2025
BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia
Stephen Jun Fei Chong, Junyan Lu, Rebecca Valentin, et al.
Biorxiv : the Preprint Server for Biology
|
November 28, 2023
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine
Alberto J Arribas, Eugenio Gaudio, Sara Napoli, et al.
Blood Advances
|
January 8, 2024
Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study
Marco Herling, Claire Dearden, Francesco Zaja, et al.
Blood
|
April 27, 2019
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
Andrew W Roberts, Shuo Ma, Thomas J Kipps, et al.
Haematologica
|
May 27, 2014
Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation
Kazuyuki Murase, Haesook T Kim, O R Gregory Bascug, et al.
Page
of 23